Adagene Inc. American Depositary Shares (ADAG)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is offering Adagene at $2.46 as of the 2026-10-13 close, a $248.4 million market value for a 128-employee clinical-stage biotech. I look first for a durable business, and here there is no commercial engine yet. The company's lead assets, ADG126 and ADG116, are antibody candidates in Phase 1b/2 cancer trials in China. That is science, not a moat; a patent or trial success can create value, but today the competitive position is unproven. Financial health is mixed. The balance sheet shows low leverage, with debt-to-equity of 0.06, and a beta of 0.56. But the income statement is weak: FairStock calculates ROE of -28.50% and ROCE of -13.95% from the provided figures. The P/B of 1.85 at the close is not demanding in isolation, but the P/E of -6.65 simply reflects losses. Quality checks are poor: Piotroski F-Score 2/9, Altman Z-Score 0.71, and a FairStock Score of 30/100. No Lynch category is assigned because only 0 years of filed results are available and three are needed. Growth cannot be judged from the data given: revenue growth and profit growth are not available. Valuation therefore rests on binary clinical outcomes, not on present earnings. Graham would demand a margin of safety; Buffett would ask for a durable franchise. Adagene has neither today. It is a speculative research option with low debt but weak financial signals, and the 52-week range of $1.30 to $4.85 shows how violently the market can reprice such hopes.

In plain English: Adagene is a small drug company testing cancer medicines in people, mainly in China. The business looks weak because it is not making money and has negative returns, and its main treatments are still in early testing. At $2.46, the price looks speculative relative to today's numbers, depending mostly on future trial results rather than current profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer